CurrentCapital BluecrossPolicy MP 1.055

Radiofrequency ablation of primary or metastatic liver tumors

Defines Capital Blue Cross medical policy MP 1.055 governing when radiofrequency ablation (RFA) of primary hepatocellular carcinoma (HCC) or hepatic metastases is considered medically necessary, investigational, or insufficient, including applicability to transplant bridging, Milan criteria, tumor origin (colorectal, neuroendocrine), and coding guidance.

Policy Summary

PayerCapital Bluecross

PolicyRadiofrequency ablation of primary or metastatic liver tumors

Policy CodePolicy MP 1.055

Change TypeAdministrative/consensus reviews (no material clinical changes)

Effective DateFeb 1, 2025

Next Review Date

Key ActionProvider must document that HCC or hepatic metastases are inoperable where indicated and that tumors meet the Milan criteria or other stated policy conditions, and verify benefit coverage and obtain any required preauthorization.

SourceLink

POLICY UPDATE CHANGES

01/19/2024 Administrative_Update_Clinical benefit added.

10/01/2024 Consensus Review. Updated NCCN recommendations, updated references.

08/07/2023 Consensus Review. Updated background and references.

01/04/2021 Consensus Review. No change to policy statement; update to references and background.

02/12/2020 Consensus Review. No change to policy statements. Coding reviewed.

4Covered Indications (distinct)

5Investigational / Not Covered Indications (listed)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary & Medical Necessity

This policy (MP 1.055) covers radiofrequency ablation (RFA) of primary hepatocellular carcinoma (HCC) and of hepatic metastases under a defined scope: RFA is considered medically necessary for primary, inoperable HCC meeting the Milan criteria, for use as a bridge to transplant, and for certain inoperable hepatic metastases of colorectal or neuroendocrine origin when specified criteria are met. The policy references the Milan criteria (single lesion ≤ 5 cm or up to 3 nodules each < 3 cm) and notes evidence gaps — RFA is supported for these inoperable indications but evidence is insufficient for many other metastatic origins and for operable HCC.

Key thresholds and policy metadata

Policy numberMP 1.055

Effective date2025-02-01

Last review2024-10-01

StatusCURRENT

SubjectRadiofrequency ablation (RFA) of primary or metastatic liver tumors

Milan criteria — single lesion size≤ 5 cm

Milan criteria — number/size of nodulesUp to 3 nodules, each < 3 cm

Medically Necessary

RFA is considered medically necessary when ALL of the following are met:

ALL of the following

ONE of
- Primary HCC as a primary treatment meeting the Milan criteria (a single tumor ≤ 5 cm OR up to 3 nodules each < 3 cm)Milan criteria: single ≤ 5 cm; up to 3 nodules each < 3 cm
- Primary HCC as a bridge to transplant where intent is to prevent tumor growth and maintain transplant candidacy
- Inoperable hepatic metastases of colorectal origin that meet the Milan criteria (a single tumor ≤ 5 cm OR up to 3 nodules each < 3 cm)Milan criteria: single ≤ 5 cm; up to 3 nodules each < 3 cm

Investigational / Not Medically Necessary

RFA is considered investigational under the following conditions:

ANY of the following

Primary, inoperable HCC when sites of tumor foci cannot be adequately treated
When used to downstage (downsize) hepatocellular carcinoma in individuals being considered for liver transplant
Primary, operable hepatocellular carcinoma (i.e., operable HCC)
Hepatic metastases from colorectal cancer or neuroendocrine tumors that do not meet the above criteria
Hepatic metastases from other types of cancer (non-colorectal, non-neuroendocrine)

What Providers Must Do

Documentation Required

Document tumor operability and Milan criteria

Provider must document that HCC or hepatic metastases are inoperable where indicated and that tumors meet the Milan criteria (single ≤5 cm or up to 3 nodules <3 cm) or other stated policy conditions (bridge to transplant, colorectal origin, neuroendocrine with refractory symptoms). Note: document inoperability and Milan criteria.

Document inoperability and reasons (location, size, comorbid conditions).
Document tumor measurements and count to confirm Milan criteria (single ≤5 cm or up to 3 nodules <3 cm).

Prior Authorization

Benefit determination and preauthorization

Coverage is subject to the member's health benefit plan and may require preauthorization; providers should verify benefit coverage and obtain any required preauthorization per the member's plan.

Verify member benefits under the applicable health benefit plan.

Codes

Relevant diagnosis codes cited in policy background/coding sectionICD-10

C22.0	Liver cell carcinoma
C22.9
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C7B.02	Secondary carcinoid tumors of liver

Coding listed in the policy (e.g., CPT codes 47370, 47380, 47382 and relevant ICD-10 diagnoses) is provided for reference; identification of a code does not by itself determine coverage. Individual claims are covered only when the service meets the medical necessity criteria in this policy and the member's benefit plan provisions.

Background & Evidence

Radiofrequency ablation (RFA) is a locoregional thermal ablation technique in which a probe or needle electrode is inserted into a tumor percutaneously, laparoscopically, or via open approach and heated by high-frequency alternating current to produce a roughly 3–5 cm sphere of coagulative necrosis. The ablated tissue undergoes fibrosis and scar formation; local recurrences, when they occur, typically arise at the treatment margin and may be retreated.

Evidence supports RFA as medically necessary for inoperable HCC meeting Milan criteria and as a bridge to liver transplantation, and for selected inoperable colorectal and neuroendocrine liver metastases when policy conditions are met. By contrast, the evidence is insufficient to support RFA for many other metastatic tumor origins and for operable HCC, where resection generally has superior outcomes.

Source/Label	Summary/Value
NCCN guidance
Category 2A recommendations for locoregional therapy/ablation; ablation may be curative for tumors ≤3 cm and should be considered in well-selected patients; tumors should be amenable to ablation with an appropriate margin and accessible location
Evidence strength for inoperable HCC
Sufficient to determine meaningful improvement in net health outcome (randomized trials, systematic reviews, meta-analyses; 3-year survival rates up to ~80% reported; supports use in inoperable HCC and as bridge to transplant)
Evidence strength for non-colorectal/non-neuroendocrine metastases
Insufficient — small nonrandomized comparative studies and case series with high risk of bias and small sample sizes; evidence does not permit general conclusion on health outcomes

Definitions

Milan criteria: single tumor ≤ 5 cm or up to 3 foci each ≤ 3 cm, with absence of angioinvasion and absence of extrahepatic involvement (used to determine transplant eligibility and applicable RFA indications).

Inoperable: Tumors not amenable to surgical resection because of location, size, number, or comorbid conditions that preclude surgery (as used in the policy context).

Bridge to transplant: Use of locoregional therapy, including RFA, to prevent tumor progression and maintain an individual's candidacy for liver transplantation while awaiting transplant.

Revision History

02/12/2020revised

02/12/2020 Consensus Review. No change to policy statements. Coding reviewed.

01/04/2021revised

01/04/2021 Consensus Review. No change to policy statement; update to references and background.

08/07/2023revised

08/07/2023 Consensus Review. No change to policy statement. Updated background and references.